-
1
-
-
84919432580
-
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
-
1 Emberson, J, Lees, KR, Lyden, P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 384 (2014), 1929–1935.
-
(2014)
Lancet
, vol.384
, pp. 1929-1935
-
-
Emberson, J.1
Lees, K.R.2
Lyden, P.3
-
2
-
-
84862629039
-
Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
-
2 Wardlaw, JM, Murray, V, Berge, E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379 (2012), 2364–2372.
-
(2012)
Lancet
, vol.379
, pp. 2364-2372
-
-
Wardlaw, J.M.1
Murray, V.2
Berge, E.3
-
3
-
-
84883769537
-
Do risks outweigh benefits in thrombolysis for stroke?
-
3 Brown, SG, Macdonald, SP, Hankey, GJ, Do risks outweigh benefits in thrombolysis for stroke?. BMJ, 347, 2013, f5215.
-
(2013)
BMJ
, vol.347
, pp. f5215
-
-
Brown, S.G.1
Macdonald, S.P.2
Hankey, G.J.3
-
4
-
-
84906706030
-
Questions about authorisation of alteplase for ischaemic stroke
-
4 Shinton, R, Questions about authorisation of alteplase for ischaemic stroke. Lancet 384 (2014), 659–660.
-
(2014)
Lancet
, vol.384
, pp. 659-660
-
-
Shinton, R.1
-
5
-
-
84926171914
-
Thrombolysis in acute ischaemic stroke: time for a rethink?
-
5 Alper, BS, Malone-Moses, M, McLellan, JS, Prasad, K, Manheimer, E, Thrombolysis in acute ischaemic stroke: time for a rethink?. BMJ, 350, 2015, h1075.
-
(2015)
BMJ
, vol.350
, pp. h1075
-
-
Alper, B.S.1
Malone-Moses, M.2
McLellan, J.S.3
Prasad, K.4
Manheimer, E.5
-
6
-
-
0028783948
-
Tissue plasminogen activator for acute ischemic stroke
-
6 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995), 1581–1587.
-
(1995)
N Engl J Med
, vol.333
, pp. 1581-1587
-
-
-
7
-
-
84862625338
-
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial
-
7 Sandercock, P, Wardlaw, JM, Lindley, RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet 379 (2012), 2352–2363.
-
(2012)
Lancet
, vol.379
, pp. 2352-2363
-
-
Sandercock, P.1
Wardlaw, J.M.2
Lindley, R.I.3
-
8
-
-
0033542395
-
Effects of tissue plasminogen activator for acute ischemic stroke at one year
-
8 Kwiatkowski, TG, Libman, RB, Frankel, M, et al., for the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 340 (1999), 1781–1787.
-
(1999)
N Engl J Med
, vol.340
, pp. 1781-1787
-
-
Kwiatkowski, T.G.1
Libman, R.B.2
Frankel, M.3
-
9
-
-
84880326684
-
Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the Third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial
-
9 IST-3 collaborative group. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the Third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial. Lancet Neurol 12 (2013), 768–776.
-
(2013)
Lancet Neurol
, vol.12
, pp. 768-776
-
-
-
10
-
-
84924034778
-
Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (Third International Stroke Trial)
-
10 Whiteley, WN, Thompson, D, Murray, G, et al. Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (Third International Stroke Trial). Stroke 45 (2014), 3612–3617.
-
(2014)
Stroke
, vol.45
, pp. 3612-3617
-
-
Whiteley, W.N.1
Thompson, D.2
Murray, G.3
-
11
-
-
39749111776
-
Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies
-
11 Slot, KB, Berge, E, Dorman, P, Lewis, S, Dennis, M, Sandercock, P, Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ 336 (2008), 376–379.
-
(2008)
BMJ
, vol.336
, pp. 376-379
-
-
Slot, K.B.1
Berge, E.2
Dorman, P.3
Lewis, S.4
Dennis, M.5
Sandercock, P.6
-
12
-
-
84908572096
-
Functional status three months after the first ischemic stroke is associated with long-term outcome: data from a community-based cohort
-
12 Magalhaes, R, Abreu, P, Correia, M, Whiteley, W, Silva, MC, Sandercock, P, Functional status three months after the first ischemic stroke is associated with long-term outcome: data from a community-based cohort. Cerebrovasc Dis 38 (2014), 46–54.
-
(2014)
Cerebrovasc Dis
, vol.38
, pp. 46-54
-
-
Magalhaes, R.1
Abreu, P.2
Correia, M.3
Whiteley, W.4
Silva, M.C.5
Sandercock, P.6
-
13
-
-
47349115423
-
Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke
-
13 Sandercock, P, Lindley, R, Wardlaw, J, et al. Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials, 9, 2008, 37.
-
(2008)
Trials
, vol.9
, pp. 37
-
-
Sandercock, P.1
Lindley, R.2
Wardlaw, J.3
-
14
-
-
82255173763
-
Update on the Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited
-
14 Sandercock, P, Lindley, R, Wardlaw, J, et al. Update on the Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials, 12, 2011, 252.
-
(2011)
Trials
, vol.12
, pp. 252
-
-
Sandercock, P.1
Lindley, R.2
Wardlaw, J.3
-
15
-
-
84858274819
-
Statistical analysis plan for the Third International Stroke Trial (IST-3); part of a ‘thread’ of reports of the trial
-
15 Sandercock, P, Lindley, R, Wardlaw, J, Whiteley, W, Murray, G, Statistical analysis plan for the Third International Stroke Trial (IST-3); part of a ‘thread’ of reports of the trial. Int J Stroke 7 (2012), 186–187.
-
(2012)
Int J Stroke
, vol.7
, pp. 186-187
-
-
Sandercock, P.1
Lindley, R.2
Wardlaw, J.3
Whiteley, W.4
Murray, G.5
-
16
-
-
0027937944
-
A simple practical classification of cerebral infarcts on CT and its interobserver reliability
-
16 Wardlaw, JM, Sellar, RJ, A simple practical classification of cerebral infarcts on CT and its interobserver reliability. AJNR Am J Neuroradiol 15 (1994), 1933–1939.
-
(1994)
AJNR Am J Neuroradiol
, vol.15
, pp. 1933-1939
-
-
Wardlaw, J.M.1
Sellar, R.J.2
-
17
-
-
0037167309
-
Thrombolysis for acute ischaemic stroke: consumer involvement in design of new randomised controlled trial
-
17 Koops, L, Lindley, RI, Thrombolysis for acute ischaemic stroke: consumer involvement in design of new randomised controlled trial. BMJ, 325, 2002, 415.
-
(2002)
BMJ
, vol.325
, pp. 415
-
-
Koops, L.1
Lindley, R.I.2
-
18
-
-
84929294516
-
Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial
-
18 Lindley, RI, Wardlaw, JM, Whiteley, WN, et al. Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial. Stroke 46 (2015), 746–756.
-
(2015)
Stroke
, vol.46
, pp. 746-756
-
-
Lindley, R.I.1
Wardlaw, J.M.2
Whiteley, W.N.3
-
19
-
-
84966357366
-
The Third International Stroke Trial (IST-3) 2000–2015 [dataset]. University of Edinburgh and Edinburgh Clinical Trials Unit
-
(accessed July 7, 2016).
-
19 Sandercock, P, Wardlaw, J, Lindley, R, Cohen, G, Whiteley, W, The Third International Stroke Trial (IST-3) 2000–2015 [dataset]. University of Edinburgh and Edinburgh Clinical Trials Unit. http://datashare.is.ed.ac.uk/handle/10283/1931, 2016 (accessed July 7, 2016).
-
(2016)
-
-
Sandercock, P.1
Wardlaw, J.2
Lindley, R.3
Cohen, G.4
Whiteley, W.5
-
20
-
-
84892614609
-
Increasing value and reducing waste: addressing inaccessible research
-
20 Chan, AW, Song, F, Vickers, A, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet 383 (2014), 257–266.
-
(2014)
Lancet
, vol.383
, pp. 257-266
-
-
Chan, A.W.1
Song, F.2
Vickers, A.3
-
21
-
-
0022640774
-
Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
-
21 Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1 (1986), 397–402.
-
(1986)
Lancet
, vol.1
, pp. 397-402
-
-
-
22
-
-
0023805341
-
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
-
22 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2 (1988), 349–360.
-
(1988)
Lancet
, vol.2
, pp. 349-360
-
-
-
23
-
-
84953395191
-
Mechanical thrombectomy in acute ischemic stroke: consensus statement by ESO-Karolinska Stroke Update 2014/2015, supported by ESO, ESMINT, ESNR and EAN
-
23 Wahlgren, N, Moreira, T, Michel, P, et al. for ESO-KSU ESO ESMINT, ESNR and EAN. Mechanical thrombectomy in acute ischemic stroke: consensus statement by ESO-Karolinska Stroke Update 2014/2015, supported by ESO, ESMINT, ESNR and EAN. Int J Stroke 11 (2016), 134–147.
-
(2016)
Int J Stroke
, vol.11
, pp. 134-147
-
-
Wahlgren, N.1
Moreira, T.2
Michel, P.3
|